The DOI matches its Crossref record; 628 of the 628 references it cites were found in a registry or an index.
Targeting cytokine and chemokine signaling pathways for cancer therapy
Open accessAbstract
Cytokines are critical in regulating immune responses and cellular behavior, playing dual roles in both normal physiology and the pathology of diseases such as cancer. These molecules, including interleukins, interferons, tumor necrosis factors, chemokines, and growth factors like TGF-β, VEGF, and EGF, can promote or inhibit tumor growth, influence the tumor microenvironment, and impact the efficacy of cancer treatments. Recent advances in targeting these pathways have shown promising therapeutic potential, offering new strategies to modulate the immune system, inhibit tumor progression, and overcome resistance to conventional therapies. In this review, we summarized the current understanding and therapeutic implications of targeting cytokine and chemokine signaling pathways in cancer. By exploring the roles of these molecules in tumor biology and the immune response, we highlighted the development of novel therapeutic agents aimed at modulating these pathways to combat cancer. The review elaborated on the dual nature of cytokines as both promoters and suppressors of tumorigenesis, depending on the context, and discussed the challenges and opportunities this presents for therapeutic intervention. We also examined the latest advancements in targeted therapies, including monoclonal antibodies, bispecific antibodies, receptor inhibitors, fusion proteins, engineered cytokine variants, and their impact on tumor growth, metastasis, and the tumor microenvironment. Additionally, we evaluated the potential of combining these targeted therapies with other treatment modalities to overcome resistance and improve patient outcomes. Besides, we also focused on the ongoing research and clinical trials that are pivotal in advancing our understanding and application of cytokine- and chemokine-targeted therapies for cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 601–628 of 628
Yang, Q., Yu, B., Kang, J., Li, A., & Sun, J. (2021) · Cancer Management and Research · doi:10.2147/cmar.s303707 · Cited by 27
Lisiero, D. N., Soto, H., Liau, L. M., & Prins, R. M. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003317 · Cited by 25
Anderson, K. S., Erick, T. K., Chen, M., Daley, H., Campbell, M., Colson, Y. L., Mihm, M. C., Zakka, L. R., Hopper, M., Barry, W. T., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06562-y · Cited by 25
Dunbar, K. J., Karakasheva, T. A., Tang, Q., Efe, G., Lin, E. W., Harris, M., Sahu, V., Sachdeva, U. M., Hu, J., Klein–Szanto, A. J., et al. (2023) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0872 · Cited by 24
Billerbeck, E., Labitt, R. N., Vega, K., Frias‐Staheli, N., Dorner, M., Xiao, J., Rice, C. M., & Ploß, A. (2014) · Immunology · doi:10.1111/imm.12304 · Cited by 23
Bempegaldesleukin (NKTR-214): a CD-122-biased IL-2 receptor agonist for cancer immunotherapy
Doberstein, S. K. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1685489 · Cited by 23
Sun, Y., Su, Y.-F., Wang, Y., Liu, N., Li, Y., Chen, J., Qiao, Z., Niu, J., Hu, J., Zhang, B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.728962 · Cited by 23
Passman, A. M., Strauss, R. P., McSpadden, S. B., Finch‐Edmondson, M., Andrewartha, N., Woo, K. H., Diepeveen, L. A., Zhao, W., Fernández‐Irigoyen, J., Santamaría, E., et al. (2021) · Cancers · doi:10.3390/cancers13194935 · Cited by 21
Zhang, F., Arnatt, C. K., Haney, K. M., Fang, H. C., Bajacan, J. E., Richardson, A. C., Ware, J. L., & Zhang, Y. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.07.049 · Cited by 20
Interdisciplinary management recommendations for toxicity associated with interferon‐alfa therapy
Hauschild, A., Kähler, K. C., Schäfer, M. K.-H., & Fluck, M. (2008) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2008.06651.x · Cited by 20
Naming the Barriers between Anti-CCR5 Therapy, Breast Cancer and Its Microenvironment
Brett, E. A., Duscher, D., Pagani, A., Daigeler, A., Kolbenschlag, J., & Hahn, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214159 · Cited by 20
Preclinical development of a humanized neutralizing antibody targeting HGF
Kim, H., Hong, S. H., Kim, J. Y., Kim, I.-C., Park, Y.-W., Lee, S.-J., Song, S.-W., Kim, J. J., Park, G., Kim, T. M., et al. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.21 · Cited by 19
Development of a novel class of interleukin-2 immunotherapies for metastatic cancer
Boyman, O., & Arenas-Ramirez, N. (2019) · Swiss Medical Weekly · doi:10.4414/smw.2019.14697 · Cited by 19
Scagliotti, G. V., Ilaria, R. L., Novello, S., von Pawel, J., Fischer, J. R., Ermisch, S., de Alwis, D. P., Andrews, J. M., Reck, M., Crinò, L., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182519d79 · Cited by 18
Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies
Noia, V. D., D’Argento, E., Pilotto, S., Grizzi, G., Caccese, M., Iacovelli, R., Tortora, G., & Bria, E. (2018) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2018.1508445 · Cited by 18
Bila, J., Katodritou, E., Guenova, M. L., Bašić‐Kinda, S., Coriu, D., Dapcevic, M., Ibricevic-Balić, L., Ivanaj, A., Каранфилски, О., Zver, S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173940 · Cited by 17
Anti-EGFR Binding Nanobody Delivery System to Improve the Diagnosis and Treatment of Solid Tumours
Wang, L., Zhang, G., Qin, L., Ye, H., Wang, Y., Long, B., & Jiao, Z. (2020) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892815666200904111728 · Cited by 16
Breast tumor metastasis following filgrastim administration due to the SDF-1/CXCR4 pathway
Khalighfard, S., Khori, V., Esmati, E., Ahmadi, F., Amiriani, T., Poorkhani, A., Sadani, S., Khodayari, S., Khodayari, H., Kalhori, M. R., et al. (2023) · Medical Oncology · doi:10.1007/s12032-022-01935-1 · Cited by 16
MABp1 for the treatment of colorectal cancer
Coyne, G. O., & Burotto, M. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1347631 · Cited by 15
Interleukin-1 signaling in solid organ malignancies
Dosch, A. R., Singh, S. P., Nagathihalli, N. S., Datta, J., & Merchant, N. B. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188670 · Cited by 15
Pan, Y., Yuan, H., Han, H., Chen, T., Ding, H., Labbe, K. E., Shum, E., Guidry, K., Hu, H., Sherman, F., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004913 · Cited by 15
Self-citationBialek-Waldmann, J. K., Heuser, M., Ganser, A., & Stripecke, R. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02406-9 · Cited by 13
Bess, S. N., Greening, G. J., Rajaram, N., & Muldoon, T. J. (2022) · BMC Immunology · doi:10.1186/s12865-022-00493-5 · Cited by 12
A receptor-antibody hybrid hampering MET-driven metastatic spread
Modica, C., Basilico, C., Chiriaco, C., Borrelli, N., Comoglio, P. M., & Vigna, E. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01822-5 · Cited by 11
IL-6 promotes MYC-induced B cell lymphomagenesis independent of STAT3
Petrenko, O., Li, J., Cimica, V., Mena, P., Shin, H. Y., D’Amico, S., & Reich, N. C. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247394 · Cited by 11
Khabipov, A., Trung, D. N., van der Linde, J., Miebach, L., Lenz, M., Erne, F., von Bernstorff, W., Schulze, T., Kersting, S., Bekeschus, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061517 · Cited by 11
Zhao, S., Zheng, X., Zhu, X., Ning, J., Zhu, K., Yan, Y., Zhang, J., Bu, J., Liu, M., & Xu, S. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1977314 · Cited by 10
Development and Validation of a Reporter-Cell-Line-Based Bioassay for Therapeutic Soluble gp130-Fc
Yu, L., Jia, C., Yao, W., Pei, D., Qin, X., Rao, C., & Wang, J. (2019) · Molecules · doi:10.3390/molecules24213845 · Cited by 5
Cited by
The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis
Nishida, A., & Andoh, A. (2025) · Cells · doi:10.3390/cells14070488 · Cited by 270
Metadata
- Authors
- Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-07-22
- Volume
- 9
- Issue
- 1
- Pages
- 176-176
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4400867712
- Cited by
- 455
- References
- 628
- FWCI
- 69.83
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.